mBio
(Oct 2021)
Revisiting an IgG Fc Loss-of-Function Experiment: the Role of Complement in HIV Broadly Neutralizing Antibody b12 Activity
Benjamin S. Goldberg,
Chengzi I. Kaku,
Jérémy Dufloo,
Timothée Bruel,
Olivier Schwartz,
David A. Spencer,
Ann J. Hessell,
Margaret E. Ackerman
Affiliations
Benjamin S. Goldberg
Thayer School of Engineering, Dartmouth College, Hanover, New Hampshire, USA
Chengzi I. Kaku
Thayer School of Engineering, Dartmouth College, Hanover, New Hampshire, USA
Jérémy Dufloo
Virus and Immunity Unit, Department of Virology, Institut Pasteur, Paris, France
Timothée Bruel
Virus and Immunity Unit, Department of Virology, Institut Pasteur, Paris, France
Olivier Schwartz
Virus and Immunity Unit, Department of Virology, Institut Pasteur, Paris, France
David A. Spencer
Division of Pathobiology and Immunology, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA
Ann J. Hessell
Division of Pathobiology and Immunology, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA
Margaret E. Ackerman
ORCiD Thayer School of Engineering, Dartmouth College, Hanover, New Hampshire, USA
DOI
https://doi.org/10.1128/mBio.01743-21
Journal volume & issue
Vol. 12,
no. 5
Abstract
Read online
Given the suboptimal outcome of VRC01 antibody-mediated prevention of HIV-1 infection in its first field trial, means to improve diverse antiviral activities in vivo
WeChat QR code
Close
